Edgar Filing: ENDOCYTE INC - Form 8-K

ENDOCYTE INC Form 8-K October 11, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 11, 2013


Endocyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.)

3000 Kent Avenue, Suite A1-100

Edgar Filing: ENDOCYTE INC - Form 8-K



Edgar Filing: ENDOCYTE INC - Form 8-K

Item 7.01 Regulation FD Disclosure.

The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On October 11, 2013, Endocyte, Inc. (the "Company") issued a press release announcing the outcomes of the planned independent Data Safety Monitoring Board review of the interim futility analysis for the Phase 2b TARGET trial with investigational candidate vintafolide, a copy of which press release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press release dated October 11, 2013

2

Edgar Filing:	ENDOCYTE	INC -	Form	8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 11, 2013

ENDOCYTE, INC.

By:/s/ Beth Taylor
Beth A. Taylor
Corporate Controller

3